Skip to main content

Advertisement

SpringerLink
Log in

Comorbidity of Heart Failure and Chronic Obstructive Pulmonary Disease: More than Coincidence

  • Comorbidities of Heart Failure (CE Angermann, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Heart failure and COPD are very common in the elderly. As both syndromes share common risk factors, such as tobacco smoking, and pathophysiological pathways, including systemic inflammation and activation of the neurohumoral system, they frequently coincide. Because of the similar clinical presentation, diagnoses of COPD in the presence of heart failure may be difficult. If spirometry is performed, caution should be taken in the interpretation of the data, as heart failure by itself (in the absence of true COPD) may exert restrictive as well as obstructive alterations in pulmonary function testing. Once COPD is established, concurrent heart failure may impact on the accurate management of these patients as severity grading of COPD could easily be overrated, and thus there is a risk of overuse of pulmonary medication, with the risk of causing cardiac side-effects. The present review focuses on the pathophysiological interrelation of comorbid COPD and heart failure, and provides practical help on how to deal with both diseases in daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med. 1995;333(23):1547–53.

    CAS  PubMed  Google Scholar 

  2. Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through clinical examination. J Gen Intern Med. 1993;8(7):383–92.

    CAS  PubMed  Google Scholar 

  3. Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One. 2013;8(3):e59225.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012;14(7):718–29.

    PubMed  Google Scholar 

  5. van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135(2):368–77.

    PubMed  Google Scholar 

  6. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–94.

    PubMed  Google Scholar 

  7. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264(4):361–9.

    CAS  PubMed  Google Scholar 

  8. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130–9.

    PubMed Central  PubMed  Google Scholar 

  9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. Guidelines on heart failure. Also mentioning COPD as an important comorbidity.

    PubMed  Google Scholar 

  10. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50.

    PubMed  Google Scholar 

  11. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.

    CAS  PubMed  Google Scholar 

  12. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–12.

    CAS  PubMed  Google Scholar 

  13. Kachel RG. Left ventricular function in chronic obstructive pulmonary disease. Chest. 1978;74(3):286–90.

    CAS  PubMed  Google Scholar 

  14. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20–2.

    PubMed  Google Scholar 

  15. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med Off J Soc Acad Emerg Med. 2003;10(3):198–204.

    Google Scholar 

  16. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006;8(7):706–11.

    PubMed  Google Scholar 

  17. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.

    CAS  PubMed  Google Scholar 

  18. van Dijk WD, Gupta N, Tan WC, Bourbeau J. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD. 2013;11(1):113–20.

    PubMed  Google Scholar 

  19. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.

    CAS  PubMed  Google Scholar 

  20. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268–73.

    CAS  PubMed  Google Scholar 

  21. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not <70 %. Chest. 2007;131(2):349–55.

    PubMed  Google Scholar 

  22. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.

    CAS  PubMed  Google Scholar 

  23. Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC, et al. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol Off J German Cardiac Soc. 2012;101(8):637–45.

    Google Scholar 

  24. Minasian AG, van den Elshout FJ, Dekhuijzen PN, Vos PJ, Willems FF, van den Bergh PJ, et al. COPD in chronic heart failure: Less common than previously thought? Heart Lung. 2013;42(5):365–71.

    PubMed  Google Scholar 

  25. Olofson J, Bake B, Tengelin MN, Houltz B. COPD 'diagnosis' based on spirometric reference equations. Clin Respir J. 2008;2(4):214–9.

    PubMed  Google Scholar 

  26. Marks GB. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax. 2012;67(1):85–7. Article discussing critically the LLN definition for diagnosing COPD.

    PubMed  Google Scholar 

  27. Wollmer P, Engstrom G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: An outcome study. Respir Med. 2013;107(9):1460–2.

    PubMed  Google Scholar 

  28. Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res. 2012;13(1):13. Study showing that hyperinflation is useful to improve the diagnosis of COPD.

    PubMed Central  PubMed  Google Scholar 

  29. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–51.

    CAS  PubMed  Google Scholar 

  30. Moons KG, Grobbee DE. When should we remain blind and when should our eyes remain open in diagnostic studies? J Clin Epidemiol. 2002;55(7):633–6.

    PubMed  Google Scholar 

  31. Jorge S, Becquemin MH, Delerme S, Bennaceur M, Isnard R, Achkar R, et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc Disord. 2007;7:16.

    PubMed Central  PubMed  Google Scholar 

  32. Assayag P, Benamer H, Aubry P, de Picciotto C, Brochet E, Besse S, et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol. 1998;82(4):459–64.

    CAS  PubMed  Google Scholar 

  33. West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet. 1992;340(8822):762–7.

    CAS  PubMed  Google Scholar 

  34. Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16(6):461–74.

    PubMed  Google Scholar 

  35. Guder G, Rutten FH, Brenner S, Angermann CE, Berliner D, Ertl G, et al. The impact of heart failure on the classification of COPD severity. J Card Fail. 2012;18(8):637–44.

    PubMed  Google Scholar 

  36. Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol. 1994;44(1):1–8.

    CAS  PubMed  Google Scholar 

  37. Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998;92(12):1321–5.

    CAS  PubMed  Google Scholar 

  38. Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation. 1999;99(9):1190–6.

    CAS  PubMed  Google Scholar 

  39. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143(3):429–33.

    CAS  PubMed  Google Scholar 

  40. Petermann W, Barth J, Entzian P. Heart failure and airway obstruction. Int J Cardiol. 1987;17(2):207–9.

    CAS  PubMed  Google Scholar 

  41. Kee K, Naughton MT. Heart failure and the lung. Circ J Off J Jpn Circ Soc. 2010;74(12):2507–16.

    Google Scholar 

  42. Brenner S, Guder G, Berliner D, Deubner N, Frohlich K, Ertl G, et al. Airway obstruction in systolic heart failure - COPD or congestion? Int J Cardiol 2013. Study that assessed serial spirometry measurements in patients hospitalized for acute decompensated systolic heart failure. It showed that COPD would be overdiagnosed when based on spirometry at the end of hospitalisation as compared to pulmonary function testing six months later when the same HF patients were in a stable phase of their heart failure. Detection of hyperinflation would improve the diagnosis of COPD, and could be performed during hospitalization.

  43. Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chronic Obstructive Pulm Dis. 2006;1(4):381–400.

    Google Scholar 

  44. US Surgeon General: The health consequences of smoking. Chronic obstructive lung disease. A report of the Surgeon General Rockville, Maryland: US Department of Health and Human Services; Public Health Service; 1984 [http://www.surgeongeneral.gov/library/reports/index.html], DHHS (PHS) 84–50205. In.; 1984.

  45. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.

    CAS  PubMed  Google Scholar 

  47. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.

    CAS  PubMed  Google Scholar 

  48. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002.

    CAS  PubMed  Google Scholar 

  49. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–5. discussion 715–716.

    CAS  PubMed Central  PubMed  Google Scholar 

  50. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–9.

    PubMed  Google Scholar 

  51. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(2):119–29.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–9.

    PubMed  Google Scholar 

  53. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:5s–13.

    CAS  PubMed  Google Scholar 

  54. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258–66. discussion 290–251.

    CAS  PubMed Central  PubMed  Google Scholar 

  55. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

    CAS  PubMed  Google Scholar 

  56. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.

    CAS  PubMed  Google Scholar 

  57. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010;7(1):5–10.

    PubMed  Google Scholar 

  58. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–82.

    PubMed  Google Scholar 

  59. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28(6):1245–57.

    CAS  PubMed  Google Scholar 

  60. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107(11):1486–91.

    CAS  PubMed  Google Scholar 

  61. Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation. 2003;107(11):1460–2.

    PubMed  Google Scholar 

  62. Javed Q, Murtaza I. Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 2013;22(5):323–7.

    PubMed  Google Scholar 

  63. Rutten F: Diagnosis and management of heart failure in COPD. Eureopean Respiratory Monogram 2013.

  64. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Eval Manag Chest. 1991;99(3):715–23.

    CAS  Google Scholar 

  65. Burghuber O, Bergmann H, Silberbauer K, Hofer R. Right ventricular performance in chronic air flow obstruction. Respiration. 1984;45(2):124–30.

    CAS  PubMed  Google Scholar 

  66. Morrison DA, Adcock K, Collins CM, Goldman S, Caldwell JH, Schwarz MI. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol. 1987;9(6):1219–29.

    CAS  PubMed  Google Scholar 

  67. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618–24.

    PubMed  Google Scholar 

  68. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax. 2003;58(7):556–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  69. Mancini GB, Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med. 2005;28(3):118–26.

    CAS  PubMed  Google Scholar 

  70. Aronow WS. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003;9(3):142–7.

    CAS  PubMed  Google Scholar 

  71. Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest. 2003;124(3):1090–102.

    PubMed  Google Scholar 

  72. Sakamaki F, Satoh T, Nagaya N, Kyotani S, Nakanishi N, Ishida Y. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest. 1999;116(6):1575–81.

    CAS  PubMed  Google Scholar 

  73. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ. 2000;320(7228):167–70.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837–49.

    PubMed  Google Scholar 

  75. Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003;123(5):1416–24.

    PubMed  Google Scholar 

  76. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J Suppl. 2003;46:81s–6.

    CAS  PubMed  Google Scholar 

  77. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11(12):1182–8.

    PubMed  Google Scholar 

  78. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101(3):353–8.

    PubMed  Google Scholar 

  79. Kwon BJ, Kim DB, Jang SW, Yoo KD, Moon KW, Shim BJ, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010;12(12):1339–44.

    PubMed  Google Scholar 

  80. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–7.

    PubMed  Google Scholar 

  81. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.

    CAS  PubMed Central  PubMed  Google Scholar 

  82. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.

    CAS  PubMed  Google Scholar 

  83. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795–807.

    PubMed  Google Scholar 

  84. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127–38. Detailed overview of caveats of betablocker and beta-agonist therapy in patients with COPD and heart failure.

    CAS  PubMed  Google Scholar 

  85. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–7.

    PubMed  Google Scholar 

  86. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007;9(8):827–33.

    CAS  PubMed  Google Scholar 

  87. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12(6):557–65.

    PubMed  Google Scholar 

  88. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther. 2008;21(1):115–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38(3):256–62.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.

    PubMed Central  PubMed  Google Scholar 

  91. Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J. 2006;27(5):972–9.

    CAS  PubMed  Google Scholar 

  92. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.

    PubMed Central  PubMed  Google Scholar 

  93. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005;26(2):159–64.

    CAS  PubMed  Google Scholar 

  94. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123(6):1964–9.

    CAS  PubMed  Google Scholar 

  95. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.

    CAS  PubMed  Google Scholar 

  96. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571–9.

    PubMed  Google Scholar 

  97. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2012;9, CD009157.

    PubMed  Google Scholar 

  98. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.

    CAS  PubMed  Google Scholar 

  99. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–103.

    CAS  PubMed  Google Scholar 

  100. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–85.

    PubMed  Google Scholar 

  101. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium–the FDA's conclusions. N Engl J Med. 2010;363(12):1097–9.

    CAS  PubMed  Google Scholar 

  102. Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. International journal of chronic obstructive pulmonary disease. 2013;8:405–23.

    PubMed Central  PubMed  Google Scholar 

  103. Reid DJ, Carlson AA. Clinical use of aclidinium in patients with COPD. International journal of chronic obstructive pulmonary disease. 2014;9:369–79.

    PubMed Central  PubMed  Google Scholar 

  104. Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug, healthcare and patient safety. 2013;5:49–55.

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Greenberger PA, Cranberg JA, Ganz MA, Hubler GL. A prospective evaluation of elevated serum theophylline concentrations to determine if high concentrations are predictable. The American journal of medicine. 1991;91(1):67–73.

    CAS  PubMed  Google Scholar 

  106. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13–24.

    PubMed  Google Scholar 

  107. White WB, Cooke GE, Kowey PR, Calverley PM, Bredenbroker D, Goehring UM, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144(3):758–65.

    CAS  PubMed  Google Scholar 

  108. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3, CD010844.

    PubMed  Google Scholar 

  109. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29(8):891–905.

    CAS  PubMed  Google Scholar 

  110. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;4, CD008989.

    PubMed  Google Scholar 

  111. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56.

    PubMed  Google Scholar 

Download references

Acknowledgments

Gülmisal Güder was supported by a fellowship grant from the Medical Faculty of the University of Würzburg (Habilitationsstipendium). This work was supported by grants from the German Ministry of Education and Research (BMBF), Berlin, Germany [BMBF 01EO1004 – Comprehensive Heart Failure Center Würzburg].

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Gülmisal Güder and Frans H. Rutten declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany

    Gülmisal Güder

  2. Department of Internal Medicine – Cardiology, University Hospital Würzburg, Würzburg, Germany

    Gülmisal Güder

  3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, PO Box 85060, Stratenum 6.101, 3508 AB, Utrecht, Netherlands

    Gülmisal Güder & Frans H. Rutten

Authors
  1. Gülmisal Güder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frans H. Rutten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frans H. Rutten.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Güder, G., Rutten, F.H. Comorbidity of Heart Failure and Chronic Obstructive Pulmonary Disease: More than Coincidence. Curr Heart Fail Rep 11, 337–346 (2014). https://doi.org/10.1007/s11897-014-0212-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-014-0212-x

Keywords

Search

Navigation